Trial Profile
The effects of Xolair (omalizumab) on airway hyperresponsiveness.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Allergic asthma
- Focus Therapeutic Use
- 22 Sep 2011 Planned end date changed from 1 Sep 2010 to 1 Sep 2011 as reported by ClinicalTrials.gov.
- 28 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 16 Feb 2010 Planned end date changed from 1 Aug 2008 to 1 Sep 2010 as reported by ClinicalTrials.gov.